勵晶太平洋(00575.HK):中期股東應佔虧損221.5萬美元
格隆匯8月27日丨勵晶太平洋(00575.HK)發佈公告,截至2025年6月30日止六個月,公司股東應佔虧損約221.5萬美元,上年同期公司股東應佔虧損約262.1萬美元。Senstend™於中國的進展方面,江蘇萬邦醫藥的主要目標仍爲於2025年底前獲得入市批準,並預計於2026年第一季度開始首次商業化上市。倘國家藥品監督管理局授予Senstend™進口許可證,江蘇萬邦醫藥將須向集團支付500萬美元(扣除中國預扣稅前)。此外,Senstend™於中國進行首次商業銷售後,江蘇萬邦醫藥將須向集團支付200萬美元(扣除中國預扣稅前)。
Fortacin™於美國的進展方面,公司已評估兩家知名臨牀研究機構關於在美國開展第三期臨牀研究的方案並正與多家制藥公司討論“對外授權”Fortacin™在美國市場的授權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.